Antimicrobial stewardship program at a tertiary care academic medical hospital: Clinical, microbiological and economic impact. A 5-year temporary descriptive study

Alfredo Jover-Sáenz a,*, María Fernanda Ramírez-Hidalgo a, Montserrat Vallverdú Vidal b, Merce García González c, Santiago Manuel Cano Marrón d, Alfredo Escartín Arias e, Miquel Falguera Sacrest f, Dolors Castellana-Perelló a, Fernando Barcenilla-Gaite a,**, on behalf of Translational Research Group on Infectious Diseases of Lleida (Head Group, TRIDLE- IRBLleida) g

a Unidad Territorial de control de Infección Nosocomial, Hospital Universitari Arnau de Vilanova, Lleida, Spain
b Servicio de Medicina Intensiva, Hospital Universitari Arnau de Vilanova, Lleida, Spain
c Unidad de Microbiología, Hospital Universitari Arnau de Vilanova, Lleida, Spain
d Servicio de Farmacia, Hospital Universitari Arnau de Vilanova, Lleida, Spain
e Servicio de Cirugía General y Aparato Digestivo, Hospital Universitari Arnau de Vilanova, Lleida, Spain
f Servicio de Medicina Interna, Hospital Universitari Arnau de Vilanova, Lleida, Spain
g Institut de Recerca Biomèdica de Lleida, Lleida, Spain

ARTICLE INFO

Article history:
Received 19 November 2019
Accepted 16 February 2020
Available online 28 February 2020

Keywords:
Antimicrobial stewardship
Use antimicrobials
Multidrug-resistant organisms
Antibiotics cost

ABSTRACT

Introduction: Few prospective studies analyze, with sufficient duration, the impact of an antimicrobial stewardship program (AMSP) carried out entirely in a hospital.

Methods: Descriptive study evaluating the consumption of antimicrobials expressed in defined daily doses (DDD) per 100 hospital occupied bed-days (OBDs) stratified in medical, surgical and intensive care unit (ICU) and the incidence of densities (ID) per 1,000 hospital OBDs of the prevalent multidrug-resistant organisms (MDRO) in a tertiary hospital, over a period of 5 years before and after the implementation of an AMSP. Analysis of direct costs and those associated with hospital stay and mortality.

Results: A total of 32,802 patients with antibiotic treatment were included in the intervention period (2013–2017). Non-imposed advice was exercised in 14.9%. The degree of adherence to recommendation was 87.9%, direct treatment and de-escalation being the most frequently admitted interventions (P<0.001). Overall hospital consumption of antibacterials in DDD/100s decreased by 5.7% (77.04 vs. 71.33) between 2008 and 2017. In ICU, the average DDD/100s showed a reduction from 155 to 113 (mean difference -18, P=0.005). There was a decrease in the DI/1000 OBDs of MDROs in the post-intervention

* Corresponding author. Unidad Territorial de control de la Infecció Nosocomial, Hospital Universitari Arnau de Vilanova, Avd Rovira Roure, 80, 25198, Lleida, Spain.
** Corresponding author.
E-mail addresses: ajover.lleida.ics@gencat.cat (A. Jover-Sáenz), fbarcenilla.lleida.ics@gencat.cat (F. Barcenilla-Gaite).
Introduction

Antibiotic resistance is a serious health problem with rapid spread worldwide. In 2019, the presence of multidrug-resistant organism (MDRO) outbreaks is considered one of the top 10 global risk factors according to Word Economic Forum [1]. By 2050, antimicrobial resistance is expected to be the leading cause of death attributable to infection [2].

Recently, several nations at the United Nations Assembly asked for the implementation of corrective measures [3]. Intervention strategies include prescribers, patients, pharmaceutical industry and general health providers [4]. One of the most effective interventions is the implementation of an antimicrobial stewardship program (AMSP), especially in hospitals [5,6]. AMSPs show a positive impact on the reduction of stays, shortening treatment duration, and minimizing the incidence of resistant bacteria infection [7,8]. However, there are only a few studies that, prospectively and with long-term maintenance, evaluate their effect beyond an action on critical patients [9], groups of specific antimicrobials [10] or the presence of remarkable microorganisms [11].

The main objective of our study is to assess the impact of an AMSP on a General Hospital over 5 years. The hypothesis formulated is how the establishment of an institutional AMSP could contribute to a reduction in the consumption of antibiotics, the presence of MDROs and their cost.

Methods

Study design

This is a prospective intervention study with historic cohort (before and after). The prospective study period was from January 2013 to December 2017 (5 years) compared to an equivalent pre-intervention period where AMSP actions had not been established.

Study setting

The study was carried out in a 400-bed General University Hospital belonging to the public health network of Catalonia (CatSalut), Spain, with a reference population of 450,000 inhabitants. It is a tertiary hospital that has several medical and surgical specialties, except transplant program, as well as an Intensive Care Unit (ICU) (32 beds). Since 1999, the hospital has had a Hospital-acquired Infection Control Unit (HICU) recognized in the institution that has been actively monitoring intra-hospital infections by MDRO and outbreak control. Annually, the center participates in the surveillance and prevention of Hospital-acquired Infections of Catalan hospitals (VINCat) [12] and is attached to the Zero Infection Projects sponsored by the Spanish Ministerio de Sanidad y Asuntos Sociales [13,14].

AMSP program design

The program included the following actions: 1. Biennial development and updating of diagnostic protocols and antibiotic treatment of the most prevalent infections; 2. Training of professionals; 3. Daily review of all positive microbiological results; 4. Daily written non-imposed advice for professionals on computerized SAP “Systems, Applications, Products in Data Processing” medical history, advice on site or by telephone. The actions could take place in relation to any positive microbiological result and/or systemic antibiotic prescription made for admitted patients. The consulting emphasized the suitability of empirical therapy, targeted treatments, dose adjustments, drug monitoring, de-escalating, early enteral conversions, shortening duration, toxicity or interaction; 5. On-site enhancement of advice in specific units (ICU and Hematology); 6. Perform annual consumption monitoring reports, density of incidence of MDROs and local microbiological sensitivity.

No restrictive measures were made to prescriptions. Adherence to the recommendations was evaluated at 24–48h from intervention. The information was collected prospectively to quantify the degree of acceptance.

Measurement of consumption, microbiological and economic impact

The primary outcome was the change in global antimicrobial hospital consumption, stratified by medical (MS), surgical (SS) and ICU services, before and after AMSP implementation. That is from 2008 to 2012 (first pre-intervention period) and between 2013 and 2017 (second post-intervention period). The secondary outcome was the trend in the evolution of common MDROs (Methicillin-resistant *Staphylococcus aureus*—MRSA—,
A total of 67,362 patients with antibiotic treatment were included; 34,560 in the period before intervention (2008–2012) and 32,802 in the intervention period (2013–2017), with 212,872 and 194,330 hospital stays, respectively. During the intervention period, 5,825 cases of advice were exercised in 4,920 patients (14.9%), highlighting general surgery and internal medicine among the services advised (43.3%). Of these, 57.2% were men with an average age of 76 years (range 20–97 years).

The degree of acceptance of the advice was 87.9%, the most accepted intervention being targeted and de-escalated therapy according to microbiological results at 29.5% (P<0.001). Specifically in MSs, early enteral conversion (P=0.001) and drug monitoring (P=0.003), and in SSSs the discontinuation of treatment (P=0.023).

DDD/100 OBDs for each antibiotic divided into groups used in general hospital and by type of service, in each study period, are shown in Table 1. The overall hospital consumption of antibacterials in DDD/100 OBDs decreased by 5.7% (77.04 vs 71.33) between 2008 and 2017 although not significantly (P=0.395) (Figure 1). In ICU, the DDD/100 OBDs showed the most significant decline, from 155 (9.24) in 2008–12 to 113 (17.4) in 2013–17 (mean difference -18, P=0.005). Annual changes in antimicrobial consumption by DDD/100s in pre- and post-intervention period globally and according to type of service are shown in Figure 2.

After the implementation of the AMSP there was an annual downward trend in DDD/100 OBDs inverse to the previous trend in the period 2008–12, this behavior being significantly different in both periods, particularly in the use of carbapenems (P=0.050), monobactams (P=0.043), fluoroquinolones (P=0.015), antipseudomonics (P=0.009), tetacyclines (P=0.024), colistin (P<0.001) and glycopeptides, especially teicoplanin (P=0.001). Many antibiotics also decreased in 2013, such as linezolid -0.55; 95% IC [-0.86, -0.23] (P=0.010), daptomycin (P=0.013) and piperacillin-tazobactam (P=0.030). In contrast, cephalosporins tended to increase annually in the period 2008–12, and then increased in post-intervention (p=0.020) at the expense of cefazolin (P=0.013), ceftriaxone/cefotaxime (P=0.010) and ceftazidime compared with cefepime (P=0.004). Azithromycin (P=0.029) and cloxacillin also increased (P=0.030) in the second period. Sulfamethoxazole-Trimetoprim showed no significant annual trend in any of the periods, but an average increase in 2013 of 0.72; 95% IC [0.23, 1.20], (P=0.010). All other antibiotics showed insignificant data. Sequential therapy maintained a decrease in the previous period (2008–12), with an annual change of -0.69; 95% IC [-1.26, -0.12], (P=0.030) that disappears in the subsequent period when an annual trend was not significant (P=0.78). In ICU, a significant reduction in prescription was observed, when the intervention started in 2013, of -17.69; 95% IC [-25.56, -9.82], (P=0.010) in carbapenems and -4.48, 95% CI [-8.36, -0.59], (p=0.030) in fluoroquinolones but with no subsequent significant annual decrease. Macrolides decreased in post-intervention period. Aminoglycosides experienced a significant increase of +8.07; 95% CI [1.71, 14.42], (P=0.020) and cephalosporins lost the downward trend in the pre-intervention period (P=0.014). In MSs, carbapenems showed a significant increase in the pre-intervention period +0.61; 95% IC [0.25, 0.97], (P=0.010) which is fully reversed in the post-intervention period (P=0.001). Finally in SSSs, lincomamides and aminoglycosides reversed the upward trend of the pre-intervention period (P=0.040) following an opposite pattern in the next period (P=0.025) and cephalosporins suffered from a significant increase in 2013 of +6.61; 95% IC [0.78, 12.45], (P=0.030) which was subsequently maintained annually (P=0.008).
Figure 1. Fitted growth curve in the general hospital’s consumption of antimicrobials in DDD/100 hospital occupied bed-days (OBDs) and according to type of service. G: general; M: medical; MS: medical-surgery; S: surgery; ICU: intensive care unit; OBD: occupied bed-days.

Table 1
Defined daily doses (DDD) per 100 hospital occupied bed-days (OBDs) in the consumption of antibacterials, before and after the implementation of AMSP, in the hospital and according to type of service

| Antimicrobial classes | Hospital P* overall | ICU P* overall | MS P* overall | SS P* overall | AMSP | Non AMSP | AMSP | Non AMSP |
|-----------------------|---------------------|----------------|---------------|---------------|------|----------|------|----------|
|                       | 2008–12             | 2013–17        | 2008–12       | 2013–17       |      |          |      |          |
| Penicillins           |                     |                |               |               |      |          |      |          |
| 1st generation        | 28.0                | 27.2           | 0.368         | 40.4          | 37.2 | 0.419    | 25.2 | 30.9     | 0.020 | 29.1 | 22.4 | 0.011 |
| 2nd generation        | 13.6                | 16.3           | 0.061         | 25.2          | 28.8 | 0.154    | 11.2 | 13.2     | 0.127 | 14.3 | 17.8 | 0.089 |
| 3rd generation        | 6.34                | 9.76           | 0.001         | 8.54          | 19.0 | <0.001   | 9.04 | 9.46     | 0.842 | 4.99 | 8.30 | 0.128 |
| 4th generation        | 2.47                | 2.07           | 0.126         | 15.08         | 9.12 | 0.001    | 2.61 | 2.57     | 0.745 | 0.67 | 0.61 | 0.375 |
| Carbapenems           | 4.60                | 3.77           | 0.102         | 21.3          | 9.10 | <0.001   | 3.12 | 3.73     | 0.346 | 3.83 | 3.08 | 0.090 |
| Monobactam            | 0.05                | 0.08           | 0.355         | 0.01          | 0.09 | 0.257    | 0.05 | 0.13     | 0.239 | 0.05 | 0.03 | 0.551 |
| Fluoroquinolones      | 11.0                | 10.0           | 0.272         | 12.1          | 4.14 | <0.001   | 13.1 | 14.1     | 0.491 | 8.75 | 6.97 | 0.048 |
| Macrolides            | 3.78                | 4.05           | 0.776         | 1.87          | 3.26 | 0.147    | 5.96 | 5.98     | 0.990 | 1.92 | 2.28 | 0.451 |
| Aminoglycosides       | 3.06                | 2.95           | 0.745         | 6.39          | 6.45 | 0.976    | 2.67 | 2.51     | 0.755 | 3.08 | 2.93 | 0.694 |
| Glycopeptides         | 1.96                | 1.54           | 0.546         | 1.98          | 3.13 | 0.126    | 2.70 | 1.15     | 0.034 | 1.26 | 1.72 | 0.576 |
| Glicilcyclines        | 0.25                | 0.22           | 0.453         | 0.25          | 1.14 | <0.001   | 0.02 | 0.06     | 0.001 | 0.10 | 0.26 | 0.003 |
| Colistin              | 1.69                | 0.37           | <0.001        | 17.88         | 2.67 | <0.001   | 0.52 | 0.28     | 0.022 | 0.22 | 0.14 | 0.450 |
| Oxazolidinones        | 0.87                | 0.97           | 0.485         | 7.55          | 2.70 | <0.001   | 0.39 | 0.76     | 0.050 | 0.25 | 0.95 | 0.003 |
| Sulfamides and        | 0.89                | 1.55           | 0.001         | 2.76          | 4.61 | 0.028    | 1.47 | 2.28     | 0.007 | 0.37 | 0.89 | 0.009 |
| trimethoprim          |                     |                |               |               |      |          |      |          |
| Lincosamides          | 1.10                | 1.07           | 0.821         | 0.71          | 1.32 | 0.140    | 0.48 | 0.92     | 0.010 | 1.78 | 1.34 | 0.098 |
| Metronidazole         | 2.03                | 3.25           | 0.014         | 1.05          | 2.06 | 0.069    | 0.78 | 1.28     | 0.126 | 3.34 | 5.37 | 0.625 |
| Tetraciclincs         | 0.36                | 0.53           | 0.015         | 3.44          | 1.81 | 0.034    | 0.40 | 0.73     | 0.077 | 0.44 | 0.64 | 0.377 |
| Lipoglycopeptides     | 0.53                | 1.28           | 0.015         | 4.17          | 4.44 | 0.876    | 0.35 | 1.16     | 0.023 | 0.24 | 0.96 | 0.001 |
| Antipseudomonal       | 19.3                | 16.2           | 0.090         | 10.15         | 5.41 | <0.001   | 3.21 | 3.28     | 0.852 | 2.10 | 1.93 | 0.572 |
| Antibiotics           |                     |                |               |               |      |          |      |          |
| resistant gram +      | 4.80                | 6.70           | 0.350         | 2.83          | 3.11 | 0.450    | 0.51 | 0.91     | 0.520 | 0.58 | 0.84 | 0.826 |
| antibiotics<sup>a</sup> |          |                |               |               |      |          |      |          |

AMSP: antimicrobial stewardship program; *Statistical significance; ICU: intensive care unit; MS: medical services (internal medicine, cardiology, neurology, pneumology, gastroenterology, rheumatology, nephrology, hematology and oncology); SS: surgical services (otorhinolaryngology, ophthalmology, traumatology and orthopedics, general surgery, vascular surgery, neurosurgery, gynecology and obstetrics, urology and maxillofacial surgery).

<sup>a</sup> Piperacillin-tazobactam, ceftazidime, cefoprocxacin, meropenem, amikacin, colistin, fosfomycin, aztreonam.

<sup>b</sup> Vancomycin, daptomycin, cotrimoxazole, tigecycline, doxycycline, linezolid, clindamycin.
Impact on microbial resistance

From 2008-2012, the hospital had an average DI/1,000 OBDs of MDROs of 0.98 vs 0.75/1,000 OBDs in 2013–2017 ($P<0.030$). There is a downward trend that was significant in this post-intervention period (RR 0.78; 95% IC [0.73, 0.84], $P<0.001$) following a significant increase in 2013 ($P<0.001$). The evolution in DI/1000 OBDs of MDROs is shown in Figure 3. In ICU, *P. aeruginosa* and *K. pneumoniae* in the pre-intervention period experienced an annual increase but only significant in

|                      | Before AMSP (2008-12) |                          |                          | After AMSP (2013-17) |                          |                          |
|----------------------|-----------------------|--------------------------|--------------------------|---------------------|--------------------------|--------------------------|
|                      | Annual change         | 95% CI                   | $P$ value                | Annual change       | 95% CI                   | $P$ value                |
| General hospital     | -0.67                 | -4.40, 3.07              | 0.680                    | -0.35               | -5.63, 4.94              | 0.880                    |
| ICU                  | -5.53                 | -15.76, 4.70             | 0.230                    | 1.13                | -13.33, 15.6             | 0.850                    |
| Medical services     | 0.43                  | -6.51, 7.36              | 0.880                    | -3.03               | -12.84, 6.78             | 0.480                    |
| Surgical services    | -1.34                 | -5.49, 2.81              | 0.460                    | 2.19                | -3.67, 8.06              | 0.400                    |

Figure 2. Annual changes in the consumption of antimicrobials by DDD/100 hospital occupied bed-days (OBDs) in the general hospital and according to type of service before and after implementation of AMSP.
the latter microorganism ($P=0.014$), with a complete reversion in the post-intervention period with RR 0.71; 95% IC [0.56, 0.89], $P=0.004$ and RR 1.48; 95% IC [1.03, 1.30], $P=0.017$, respectively. A. baumannii maintains a downward trend in the period 2008–2012, more pronounced and significant in the second period (RR 0.20; 95% IC [0.08, 0.39], $P<0.001$). Most of the MDROs studied suffer from a significant rise in 2013. 

Clostridioides difficile maintained an unchanged DI between periods of around 0.05/1,000 OBDs, that increased in the last year of the post-intervention period (2016), following the introduction of new techniques as a diagnostic method. Multi-resistant Enterococcus spp were not found in either of the periods.

Various health indicators were monitored in order to detect other issues that could interfere with MDRO IDs (Table 2). In the post-intervention period, there was a reduction in episodes of central venous catheter-related infections in patients with parenteral nutrition (RR 0.50; 95% CI [0.43, 0.56], $P<0.001$), colon-rectum surgery rates (RR 0.65; 95% CI [0.57, 0.72], $P=0.032$) and per organ/space in colon-rectum surgery (RR 0.68; 95% CI [0.59, 0.71], $P=0.048$).

As for the crude mortality rate, there was no variation in either of the two periods, 3.34 vs 3.14 ($P=0.210$). A decrease in the annual ratio between days of stay and hospital discharge was observed in both periods, but with an upward annual pattern change in the discharges in MSs in the period 2013–2017 ($P=0.029$). The rate of hospital readmission in the first month remained almost unchanged from 6.9% to 7.0%.

**Impact on economic cost**

The average annual cost of antibacterials between MSs and Ss decreased from €1,152,151 to €835,568 (mean difference -€316,583; $P=0.001$) and in ICU went from €282,897 to €120,237 (mean difference -€162,660; $P=0.001$). The 4,330 patients in whom the advice was accepted presented 0.55 inpatient days post intervention compared with cases that ignored recommendations, generated 2,375.2 days less of hospitalization, which is quantified as an economic amount of €1,254,111. The total savings between antibacterials and days of hospitalization were €3,450,326.

**Discussion**

The rise of AMSPs in hospitals, as a consequence of concern about the negative effects of the inappropriate use of antibiotics and increased resistance, has led to an improvement in the centers that implemented them [4,5,18]. Long-term benefit is practically unknown, most experiences in the research literature not exceeding one year [19].

This study confirms how the implementation of an AMSP in a tertiary hospital and for a prolonged period, carried out by a
team of professionals exclusively specialized in infectious diseases, was associated with a reduction in consumption of antimicrobials, decreasing MDROs and favorable economic and cost savings.

The outcomes are the result of the high degree of acceptance (about 90%) of non-imposed advice, unlike the results achieved with restrictive measures as described in the literature [20]. This high percentage response has also been observed in other studies carried out in hospitals of a similar level [21]. The yield is better when they also work on the control and prevention of hospital-acquired infections [10,22]. Although advice interventions made 1–3 days a week may be effective [23], daily intervention has helped to consolidate the impact [18].

Although there are other types of measurement units in antibiotic consumption, this study has used DDD as a numerical assessment of international comparison. Our general consumption of antibacterials percentage (5.7%) is similar to other publications [19,24]. In the specific case of ICU, the reduction in DDD/100 OBDs was less (155 vs 113 (mean difference -18, ¼ 0.005)) than that observed in the literature, perhaps because they have a higher starting point of DDD in the pre-intervention period [9] and as a consequence of active surveillance projects. In contrast, the non-significant increase in antibiotic use in SSs during the intervention period may have been due to an increase on combining two antimicrobials, as an alternative to carbapenem or ureidopenicilllin monotherapy. Perhaps these are the reasons why general antibiotic reduction has not been significant.

Overall, we observed that the decrease in consumption occurred especially in the antibiotics that are associated with a greater induction of resistance and the emergence of Clostridioides difficile [14]. This reduction was achieved with early de-escalation and restriction of these antibiotics both in community infections and in empirical treatments by modifying local protocols. This is quite the opposite of what has been happening in the case of carbapenems, in other hospitals near us [25]. After the implementation of a specific AMSP, Álvarez-Lerma et al. [9] achieved a decrease in various antimicrobials, except in piperacillin-tazobactam and carbapenems. Also noteworthy is the reduction in teicoplanin compared to vancomycin (P<0.001), justifiable by the choice of the latter because of the possibility of monitoring levels and lower cost [26]. The increase in the use of ciprofloxacin was possibly caused by the substitution of lipo and glycopeptides in the cases of beta-lactamic gram-positive cocci infection.

Some studies point to a reduction in mortality and stays in the groups intervened with AMSPs. Tedeschi et al. [27] show how de-escalation is not linked to higher mortality. In the case of bacteremia, especially Staphylococcus aureus, a rapid targeted treatment even increases the cure rate, reducing relapses and mortality [28]. In our case, the crude mortality remained unchanged, although its relationship with infections could not be investigated. The stays remained stable and the discharges increased slightly, indicating that a smaller amount of antimicrobials has been consumed and that more patients have been treated with the same number of antimicrobials.

In our study we observed a global reduction in the presence of MDROs and specifically in ICU after starting the AMSP, although we do not know the main reason for exponential growth before its beginning. Karanika et al. [29] analyzed the effect of AMSPs in 7 studies in which there was a significant decrease in the presence of MDROs. In a recent meta-analysis by Baur et al. [11] of 32 studies conducted over 60 years, a reduction was shown in the incidence of infection and MDROs colonization.

From an economic point of view, our experience shows that the AMSP has been cost effective, with a potential annual saving of approximately €500,000, similar to other studies [30]. The cost of ICU staff can be financed by the indirect saving derived from the reduction in hospital stays, which in our case is around €250,822 per year.

Our work has several limitations: (1) the AMSP was applied in units with electronic medication dispensers which left out pediatrics and emergencies, (2) the introduction of Zero projects in the ICU and institutional projects in hospitalization rooms that condition the decrease in surgical infection rates in the AMSP’s period may have influenced our results.

Finally, we think that the fact that it is a prospective comparative trial with a reproducible methodology makes it possible to generalize our results.

In conclusion, the results of this study show that, after 5 years, the strategy of implementing a global AMSP in a tertiary hospital was associated with significant benefits in reducing antimicrobial consumption, protection of the ecosystem and lower economic cost, without prejudice to the patient.

### Table 2

Health variables during the study period by year

| Health Indicators                      | 2008    | 2009    | 2010    | 2011    | 2012    | 2013    | 2014    | 2015    | 2016    | 2017    |
|----------------------------------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| No. Patients                           | 19,676  | 19,654  | 20,120  | 19,677  | 19,066  | 18,278  | 18,488  | 18,522  | 18,675  | 19,192  |
| No. OBDs                               | 125,416 | 118,260 | 126,247 | 117,862 | 116,965 | 112,769 | 110,159 | 110,070 | 109,110 | 109,968 |
| No. Bacteremia associated with central vascular catheter for parenteral nutrition | 145     | 85      | 59      | 60      | 59      | 62      | 47      | 52      | 64      | 60      |
| Knee prosthesis infection rate         | 0       | 0       | 1.8     | 1       | 1.9     | 0.8     | 0       | 1.4     | 0       | 0.6     |
| Hip prosthesis infection rate          | 2.6     | 0       | 0       | 0       | 0       | 1.7     | 4.4     | 0       | 1.6     | 0       |
| Colon Surgery (CS) infection rate      | 28.7    | 14.4    | 23.9    | 25.2    | 26.7    | 15.8    | 18.1    | 21.7    | 11.9    | 9.4     |
| Organ/space infection rate in CS       | 16.1    | 8.5     | 8.3     | 10.7    | 15.8    | 4.2     | 11.4    | 11.5    | 7.9     | 5.5     |

OBDs: occupied bed-days.
Authors’ contribution

Alfredo Jover-Saénz: Conceptualization, Methodology, Writing - original draft, Supervision, Writing - review & editing; Maria Fernanda Ramirez-Hidalgo: Methodology, Validation, Writing - original draft, Writing - review & editing;Montserrat Vallverdú Vidal: Visualization, Writing - review & editing; Merce Garcia González: Resources, Writing - review & editing; Santiago Manuel Cano Marrón: Software, Methodology, Writing - review & editing; Alfredo Escartin Arias: Visualization, Writing - review & editing; Miquel Falguera Sacrest: Visualization, Writing - review & editing; Dolors Castellana-Perelló: Software, Visualization, Writing - review & editing; Fernando Barcenilla-Gaite: Conceptualization, Methodology, Supervision, Writing - review & editing.

Conflict of interest

The authors declare that they have no conflicts of interest and did not receive external financial support on conducting the study.

Acknowledgements

Our most sincere thanks to medical professionals and hospital nurses, responsible for our patients, for their support on accepting and implementing the recommendations; pharmacists, microbiologists and technicians for their invaluable contribution to the completion of advice, dosing and drug monitoring and early identification of microorganisms, and to the hospital’s technical registry for supplying the administrative information necessary for the study.

References

[1] The Global Risks Report 2019 14th Edition. Word economic forum. Available at: www.weforum.org.

[2] Public heath England. Antimicrobial resistance (AMR): applying all our health. 2019. Available at: https://www.gov.uk/government/publications/antimicrobial-resistance-amr-applying-all-our-health.

[3] World Health Organization. General Assembly of the United Nations: High-level Meeting programme and documents. Available at: http://www.un.org/pga/71/wpcontent/uploads/sites/40/2016/09/DGACM_GAEAD_ESCAB-AMR-Draft-Political-Declaration-1616108-Spanish.pdf; 2016.

[4] Cox JA, Vlieghe E, Mendelson M, Werthem H, Ndegwa L, Villegas MV, et al. Antibiotic stewardship in low and middle income countries: the same but different? Clin Microbiol Infect 2017;23:812–8.

[5] Bucket WR, Veillette JJ, Vento TJ, Stenehjem E. Antimicrobial stewardship in community hospitals. Med Clin N Am 2018;102:913–28.

[6] Nathwani D, Varghese D, Stephens J, Ansari W, Martin S, Charbonneau C. Value of hospital antimicrobial stewardship programs [ASP]: a systematic review. Antimicrob Resist Infect Control 2019;8:35.

[7] Nilholm H, Holmstrand L, Ahl J, Mansson F, Odenholt I, Tham J, et al. An audit based-infectious disease specialist guided antimicrobial stewardship program profoundly reduced antibiotic use without negatively affecting patient outcome. Open Forum Infect Dis 2015;2:ofv042.

[8] Marwick CA, Guthrie B, Davey PG. Hospital antimicrobial stewardship: the way forward. Lancet Infect Dis 2017;17:1119–20.

[9] Alvarez-Lerma F, Grau S, Echeverria-Esnal D, Martinez-Alonso M, Gracia-Arnillas MP, Horcagaja JP, et al. A Before-and-after study of the effectiveness of an antimicrobial stewardship program in critical care. Antimicrob Agents Chemother 2018;62. e01825-17.

[10] García-Rodríguez JF, Bardán-García B, Peña-Rodríguez MF, Álvarez-Díaz H, Maríno-Callejo A. Meropenem antimicrobial stewardship program: clinical, economic, and antibiotic resistance impact. Eur J Clin Microbiol Infect Dis 2019;38:161–70.

[11] Baur D, Gladstone BP, Burker F, Carrara F, Fröchi F, Dohmen S, et al. Effect of antibiotic stewardship on the incidence of infection and colonization with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis 2017;17:990–1001.

[12] VINCat Program. Programa de Vigilancia de les Infeccions Nosocomials a Catalunya. Generalitat de Catalunya. Departament de Salut. Available at: http://catsalut.gencat.cat/ca/proveidors-professionals/vinca/.

[13] Spanish Society of Intensive Care Medicine, Units Coronary, Working Group of Infectious Diseases and Sepsis (GTEIS). National Surveillance Study of Nosocomial Infection in the ICU (ENVINHELICS). Bacteremia Zero project, Pneumonia Zero project, Resistance Zero project. SEMICYUC, Madrid, Spain. Available at: http://hws.vhebron.net/envin-helics; 2018.

[14] Plan estratégico y de acción para reducir el riesgo de selección y diseminación de la resistencia a los antibióticos (2014). Agencia española de medicamentos y productos sanitarios. Ministerio de Sanidad, Servicios Sociales e Igualdad. Available at: http://www.aemps.gob.es/publicaciones/publica/planestrategico-antibioticos/v2/docs/plan-estrategico-antimicrobianos-AEMPS.pdf.

[15] Rodríguez-Baño J, Paño-Pardo JR, Álvarez-Rocha L, Asensio A, Calbo E, Cercenado E, et al. Grupo de Estudio de la Infección Hospitalaria-Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica; Sociedad Española de Farmacia Hospitalaria-Sociedad Española de Medicina Preventiva Salud Pública e Higiene. Programs for optimizing the use of antibiotics (PROA) in Spanish hospitals: GEIH-SEIMC, SEFH and SEMPSHP consensus document. Enferm Infecc Microbiol Clin 2012;22. https://doi.org/10.1016/j.eimc.2011.09.018. e122-e23. (In Spanish). Available at:

[16] Magiorakos AP, Srinivasan A, Carey RB, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268–81.

[17] Patel JB. Approved Guideline, M-02 e M-07. Clinical and laboratory standards institute; 2016. Performance standards for antimicrobial susceptibility Testing MS100–26.

[18] Beaulac K, Corcione S, Epstein L, Davidson LE, Doron S. Antimicrobial stewardship in a long-term acute care hospital using offsite electronic medical record audit. Infect Control Hosp Epidemiol 2016;37:433–9.

[19] Ugalde-Espinoza J, Bilbao-Aguirregomezcorta J, Sanjuan-López AZ, Florista-Imízcoz C, Elorduy-Otazua L, Viciola-García M. A program for optimizing the use of antimicrobials (PROA): experience in a regional hospital. Rev Esp Quimioter 2016;29:183–9.

[20] Mostaghim M, Snelling T, Bajorak B. Factors associated with adherence to antimicrobial stewardship after-hours. Int J Pharm Pract 2019;27:180–90.

[21] García-San Miguel L, Cobo J, Martínez JA, Arnau JM, Murillas J, Peña C, et al. Third day intervention: an analysis of the factors associated with following the recommendations on the prescribing of antibiotics. Enferm Infecc Microbiol Clin 2014;32:654–61.

[22] Burnham JP, Olsen MA, Stwalley D, Kwon JH, Babcock HM, Kollef MH. Infectious diseases consultation reduces 30-day and 1-year all-cause mortality for multidrug-resistant organism infections. Open Forum Infect Dis 2018;5:ofy026. https://doi.org/10.1093/ofid/ofy026.
[23] Hagiwara D, Sato K, Miyazaki M, Kamada M, Moriwaki N, Nakano T. The impact of earlier intervention by an antimicrobial stewardship team for specific antimicrobials in a single weekly intervention. Int J Infect Dis 2018;77:34–9.

[24] Jenkins TC, Knepper BC, Shihadeh K, Haas MK, Sabel AL, Steele AW. Long-term outcomes of an antimicrobial stewardship program implemented in a hospital with low baseline antibiotic use. Infect Control Hosp Epidemiol 2015;36:664–72.

[25] Grau S, Fondevilla E, Echeverría-Esnal D, Alcorta A, Limon E, Gudiol F, VINCat Program group. Widespread increase of empirical carbapenem use in acute care hospitals in Catalonia, Spain. Enferm Infecce Microbiol Clin 2019;37:36–40.

[26] Abad F, Calbo F, Zapater P, Rodríguez-Vilanova F, García-Pérez L, Sacristán JA. Comparative pharmacoeconomic study of vancomycin and teicoplanin in intensive care patients. Int J Antimicrob Agents 2000;15:65–71.

[27] Tedeschi S, Trapani F, Giannella M, Cristini F, Tumietto F, Bartoletti M. An Antimicrobial Stewardship Program Based on Systematic Infectious Disease Consultation in a Rehabilitation Facility. Infect Control Hosp Epidemiol 2017;38:76–82.

[28] Lahey T, Shah R, Gittzus J, Schwartzman J, Kirkland K. Infectious diseases consultation lowers mortality from Staphylococcus aureus bacteremia. Medicine (Baltimore) 2009;88:263–7.

[29] Karanika S, Paudel S, Grigoras C, Kalbasi A, Mylonakis E. Systematic review and meta-analysis of clinical and economic outcomes from the implementation of hospital-based antimicrobial stewardship programs. Antimicrob Agents Chemother 2016;60:4840–52.

[30] Standiford HC, Chan S, Tripoli M, Weekes E, Forrest GN. Antimicrobial stewardship at a large tertiary care academic medical center: cost analysis before, during, and after a 7-year program. Infect Control Hosp Epidemiol 2012;33:338–45.